Medicare Part D coverage · 0.8 · RxCUI 1442683
0.8 ML tbo-filgrastim 0.6 MG/ML Prefilled Syringe [Granix]
Per the CMS 2026 Part D formulary file, 0.8 ML tbo-filgrastim 0.6 MG/ML Prefilled Syringe [Granix] is covered by 573 Medicare Part D plans (11.3% of enrollable products), averaging Tier 4.5, with prior authorization required on 93% of covering formularies.
- 11.3%
- Plan coverage
- 573
- Plans covering
- T4.5
- Avg tier
- 93%
- Prior auth required
What the CMS Formulary Data Shows for 0.8 ML tbo-filgrastim 0.6 MG/ML Prefilled Syringe [Granix]
Per the CMS 2026 Part D formulary file, 0.8 ML tbo-filgrastim 0.6 MG/ML Prefilled Syringe [Granix] (RxNorm concept RXCUI 1442683, generic name 0.8) appears on 57 distinct formulary files spanning 573 Medicare Part D plan offerings - 11.3% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 5, with a cross-plan average of Tier 4.5.
Real-world access to 0.8 ML tbo-filgrastim 0.6 MG/ML Prefilled Syringe [Granix] depends on utilization management as much as tier placement: 93% of covering formularies require prior authorization. 1.8% require step therapy. 0% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 430 Part D beneficiaries filled 0.8 ML tbo-filgrastim 0.6 MG/ML Prefilled Syringe [Granix] in 2023, with total plan-and-beneficiary spending of $2,335,129 and an average per-beneficiary annual cost of $5,430.53. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry 0.8 ML tbo-filgrastim 0.6 MG/ML Prefilled Syringe [Granix] today.
Coverage Details
- Formularies covering
- 57
- Plans covering
- 573
- Coverage rate
- 11.3%
- Tier range
- Tier 1 – Tier 5
- Average tier
- Tier 5, Specialty
Restrictions
- Prior authorization required
- 93% of formularies
- Step therapy required
- 1.8% of formularies
- Quantity limits
- 0% of formularies
2023 Medicare Spending
- Beneficiaries
- 430
- Total spending
- $2,335,129
- Avg per beneficiary
- $5,430.53
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering 0.8 ML tbo-filgrastim 0.6 MG/ML Prefilled Syringe [Granix]
100 Medicare Advantage plans with Part D drug coverage include this drug.
Show the next 30 plans
Showing top 50 of 100 plans.
Frequently Asked Questions
Is 0.8 ML tbo-filgrastim 0.6 MG/ML Prefilled Syringe [Granix] covered by Medicare Part D?
Yes, 0.8 ML tbo-filgrastim 0.6 MG/ML Prefilled Syringe [Granix] is covered by 573 Medicare Part D plans (11.3% of all Part D formularies).
What tier is 0.8 ML tbo-filgrastim 0.6 MG/ML Prefilled Syringe [Granix] on Medicare Part D plans?
0.8 ML tbo-filgrastim 0.6 MG/ML Prefilled Syringe [Granix] averages Tier 4.5 across Part D plans, ranging from Tier 1 to Tier 5.
Does 0.8 ML tbo-filgrastim 0.6 MG/ML Prefilled Syringe [Granix] require prior authorization?
93% of Part D formularies require prior authorization for 0.8 ML tbo-filgrastim 0.6 MG/ML Prefilled Syringe [Granix]. Step therapy: 1.8%. Quantity limits: 0%.
How much does Medicare spend on 0.8 ML tbo-filgrastim 0.6 MG/ML Prefilled Syringe [Granix]?
In 2023, total Medicare Part D spending on 0.8 ML tbo-filgrastim 0.6 MG/ML Prefilled Syringe [Granix] was $2,335,129, covering 430 beneficiaries. The average spend per beneficiary was $5,430.53.
Read our methodology - how this data is sourced, computed, and verified.
Nationwide similar Part D drugs
Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.
Closest average formulary tier
Similar prior-authorization rate
- insulin lispro 100 UNT/ML Injectable Solution [Admelog] 93% PA
- {28 (alpelisib 50 MG Oral Granules [Vijoice]) } Pack [Vijoice 50 MG Granules 28 Day] 93% PA
- 0.6 ML pegfilgrastim-bmez 10 MG/ML Prefilled Syringe [Ziextenzo] 93.1% PA
- 0.4 ML adalimumab-adbm 100 MG/ML Prefilled Syringe 92.9% PA
- caplacizumab-yhdp 11 MG Injection [Cablivi] 93.1% PA
- 1 ML lanadelumab-flyo 150 MG/ML Prefilled Syringe [Takhzyro] 92.9% PA